Involvement of lncRNAs in the tumor microenvironment: a new property of tumor immunity

References

1. 1.↵
   2. Morad G,
   3. Helmink BA,
   4. Sharma P,
   5. Wargo JA.

   Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. Cell. 2021; 184: 5309–37.

   OpenUrlCrossRefPubMed
2. 2.↵
   2. Zeni PF,
   3. Mraz M.

   LncRNAs in adaptive immunity: role in physiological and pathological conditions. RNA Biol. 2021; 18: 619–32.

   OpenUrlCrossRef
3. 3.↵
   2. Xu S,
   3. Wang Q,
   4. Kang Y,
   5. Liu J,
   6. Yin Y,
   7. Liu L, et al.

   Long noncoding RNAs control the modulation of immune checkpoint molecules in cancer. Cancer Immunol Res. 2020; 8: 937–51.

   OpenUrlAbstract/FREE Full Text
4. 4.↵
   2. Mowel WK,
   3. Kotzin JJ,
   4. McCright SJ,
   5. Neal VD,
   6. Henao-Mejia J.

   Control of immune cell homeostasis and function by lncRNAs. Trends Immunol. 2018; 39: 55–69.

   OpenUrlCrossRefPubMed
5. 5.↵
   2. Herbst RS,
   3. Soria JC,
   4. Kowanetz M,
   5. Fine GD,
   6. Hamid O,
   7. Gordon MS, et al.

   Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014; 515: 563–7.

   OpenUrlCrossRefPubMedWeb of Science
6. 6.↵
   2. Lucibello G,
   3. Mograbi B,
   4. Milano G,
   5. Hofman P,
   6. Brest P.

   PD-L1 regulation revisited: impact on immunotherapeutic strategies. Trends Mol Med. 2021; 27: 868–81.

   OpenUrl
7. 7.↵
   2. Ghafouri-Fard S,
   3. Shoorei H,
   4. Hussen BM,
   5. Poornajaf Y,
   6. Taheri M,
   7. Sharifi G.

   Interplay between programmed death-ligand 1 and non-coding RNAs. Front Immunol. 2022; 13: 982902.
8. 8.↵
   2. Jiang W,
   3. Pan S,
   4. Chen X,
   5. Wang ZW,
   6. Zhu X.

   The role of lncRNAs and circRNAs in the PD-1/PD-L1 pathway in cancer immunotherapy. Mol Cancer. 2021; 20: 116.

   OpenUrl
9. 9.↵
   2. Park EG,
   3. Pyo SJ,
   4. Cui Y,
   5. Yoon SH,
   6. Nam JW.

   Tumor immune microenvironment lncRNAs. Brief Bioinform. 2022; 23: bbab504.
10. 10.↵
    2. Demaria O,
    3. Cornen S,
    4. Daëron M,
    5. Morel Y,
    6. Medzhitov R,
    7. Vivier E.

    Harnessing innate immunity in cancer therapy. Nature. 2019; 574: 45–56.

    OpenUrlCrossRefPubMed
11. 11.↵
    2. Zhang Y,
    3. Cao X.

    Long noncoding RNAs in innate immunity. Mol Immunol. 2016; 13: 138–47.

    OpenUrl
12. 12.↵
    2. Guo Y,
    3. Xie Y,
    4. Luo Y.

    The role of long non-coding RNAs in the tumor immune microenvironment. Front Immunol. 2022; 13: 851004.
13. 13.
    2. Yu H,
    3. Chen C,
    4. Han F,
    5. Tang J,
    6. Deng M,
    7. Niu Y, et al.

    Long noncoding RNA MIR4435-2HG suppresses colorectal cancer initiation and progression by reprogramming neutrophils. Cancer Immunol Res. 2022; 10: 1095–110.

    OpenUrl
14. 14.↵
    2. Atianand MK,
    3. Caffrey DR,
    4. Fitzgerald KA.

    Immunobiology of long noncoding RNAs. Annu Rev Immunol. 2017; 35: 177–98.

    OpenUrlCrossRefPubMed
15. 15.
    2. Pi YN,
    3. Qi WC,
    4. Xia BR,
    5. Lou G,
    6. Jin WL.

    Long non-coding RNAs in the tumor immune microenvironment: biological properties and therapeutic potential. Front Immunol. 2021; 12: 697083.
16. 16.↵
    2. De Mey W,
    3. Esprit A,
    4. Thielemans K,
    5. Breckpot K,
    6. Franceschini L.

    RNA in cancer immunotherapy: unlocking the potential of the immune system. Clin Cancer Res. 2022; 28: 3929–39.

    OpenUrl
17. 17.↵
    2. Pastor F,
    3. Berraondo P,
    4. Etxeberria I,
    5. Frederick J,
    6. Sahin U,
    7. Gilboa E, et al.

    An RNA toolbox for cancer immunotherapy. Nat Rev Drug Discov. 2018; 17: 751–67.

    OpenUrlPubMed
18. 18.↵
    2. Winkle M,
    3. El-Daly SM,
    4. Fabbri M,
    5. Calin GA.

    Noncoding RNA therapeutics - challenges and potential solutions. Nat Rev Drug Discov. 2021; 20: 629–51.

    OpenUrlCrossRefPubMed
19. 19.↵
    2. Paunovska K,
    3. Loughrey D,
    4. Dahlman JE.

    Drug delivery systems for RNA therapeutics. Nat Rev Genet. 2022; 23: 265–80.

    OpenUrlCrossRef
20. 20.↵
    2. Lin Q,
    3. Liu T,
    4. Wang X,
    5. Hou G,
    6. Xiang Z,
    7. Zhang W, et al.

    Long noncoding RNA HITT coordinates with RGS2 to inhibit Pd-L1 translation in T cell immunity. J Clin Invest. 2023; 133: e162951.
21. 21.↵
    2. Lu B,
    3. Javidi-Parsijani P,
    4. Makani V,
    5. Mehraein-Ghomi F,
    6. Sarhan WM,
    7. Sun D, et al.

    Delivering SaCas9 mRNA by lentivirus-like bionanoparticles for transient expression and efficient genome editing. Nucleic Acids Res. 2019; 47: e44.
22. 22.↵
    2. Hu Q,
    3. Ye Y,
    4. Chan LC,
    5. Li Y,
    6. Liang K,
    7. Lin A, et al.

    Oncogenic lncRNA downregulates cancer cell antigen presentation and intrinsic tumor suppression. Nat Immunol. 2019; 20: 835–51.

    OpenUrlCrossRefPubMed